WHO ICTRP trial
The effect of fat-derived stem cells in treatment of multiple sclerosis
IRCT20091127002778N1 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20091127002778N1 |
|---|---|
| Public title | The effect of fat-derived stem cells in treatment of multiple sclerosis |
| Scientific title | The effect of autologous adipose-derived mesenchymal stem cells transplantation in the treatment of multiple sclerosis in Secondary Progressive phase |
| Primary sponsor | Mashhad University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 1-2 |
| Countries | Iran (Islamic Republic of) |
| Conditions | multiple sclerosis. Demyelinating diseases of the central nervous system, multiple sclerosis;G35-G37;Demyelinating diseases of the central nervous system, multiple sclerosis |
| Interventions | intervention:Adipose-Tissue Mesenchymal Stem Cells in a amount of 5×106 MSC/Kg, each dosage include 2.5×106 MSC/Kg into MS patients, 2 dosage during 2 injection space 7 days apart.;Treatment - Drugs;intervention:Adipose-Tissue Mesenchymal… |
| Registration date | Jan 10, 2018 |
| Target size | 10 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: